No Data
No Data
Jinyu Bio-Technology (600201.SH): Repurchased 0.22 million shares for the first time.
Gelonghui, on January 22, announced that Jinyu Bio-Technology (600201.SH) has repurchased a total of 220,000 shares through centralized bidding, accounting for 0.0196% of the company's total share capital. The highest transaction price was 6.46 yuan/share, the lowest transaction price was 6.44 yuan/share, and the total amount paid was 1,419,600 yuan (excluding commission, transfer fees, and other transaction costs).
Jinyu Biotechnology Co., Ltd. 2024 Annual Performance Forecast
Jinyu Bio-Technology (600201.SH): The net profit is expected to decrease by 56.61% to 63.43% in 2024.
Gelonghui, January 17 | Jinyu Bio-Technology (600201.SH) announced its performance forecast for 2024, expecting a net income attributable to shareholders of the listed company to be between 103.72 million yuan and 123.08 million yuan, a year-on-year decrease of 56.61% to 63.43%; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be between 48.4 million yuan and 67.76 million yuan, a year-on-year decrease of 73.37% to 80.98%. In 2024, impacted by the cyclicality of the breeding industry and capacity reduction, along with clients' demand for cost reduction, the animal protection industry.
Jinyu Bio-Technology (600201.SH): Collaborated with leading figures in the domestic RNA field to establish a joint development team, creating an AI + synthetic biology innovation platform.
On December 27, Gelonghui reported that Jinyu Bio-Technology (600201.SH) stated on the interactive platform that the company has collaborated with leading figures in the domestic RNA field to establish a joint development team, creating an AI + synthetic biology innovation platform. This effort aims to position themselves early in the fourth generation vaccine—digital vaccines, gradually establishing a complete system from database construction, AI computing power, vaccine design, animal testing validation, to vaccine registration and industrialization. On one hand, AI deep learning models will be utilized to enhance the development and application of animal health products, while on the other hand, the animal health industry’s large-scale data generation capability will be leveraged to continuously optimize AI large models at various stages of vaccine research and development.
CHINARES PHARMA (03320) subsidiary CHINARES PHARMA Holdings' Shareholding in China Resources Boya Bio-pharmaceutical Group has reached 1%.
CHINARES PHARMA (03320) announced that between November 8, 2024, and December 18, 2024, public...
Jinyu Bio-technology Gets China Approval for Cattle Infection Treatment